Rhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3M
Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...
Yahoo Finance4d
Rhythm Pharmaceuticals, Inc. (RYTM)
After hours: March 21 at 7:08:45 PM EDT Loading Chart for RYTM ...
MarketWatch1d
S&P 500 Pharmaceuticals Industry Index
IPC Indice de Precios Y Cotizaciones 52,937.61 265.19 0.50% ...
Nasdaq6d
Eton Pharmaceuticals, Inc. Common Stock (ETON) Earnings
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...